|
CA114536A
(en)
|
1908-09-18 |
1908-10-13 |
Adolphe Chalas |
Nickel recovering process
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
US5420032A
(en)
|
1991-12-23 |
1995-05-30 |
Universitge Laval |
Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
|
|
US5792632A
(en)
|
1992-05-05 |
1998-08-11 |
Institut Pasteur |
Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
WO2000023573A2
(en)
|
1998-10-20 |
2000-04-27 |
City Of Hope |
Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
|
US20060078552A1
(en)
|
2002-03-15 |
2006-04-13 |
Sylvain Arnould |
Hybrid and single chain meganucleases and use thereof
|
|
US20060153826A1
(en)
|
2003-01-28 |
2006-07-13 |
Sylvain Arnould |
Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
|
|
JP2008527001A
(ja)
|
2005-01-13 |
2008-07-24 |
ザ ジョンズ ホプキンス ユニバーシティー |
前立腺幹細胞抗原ワクチンおよびその使用
|
|
CA2891996A1
(en)
|
2005-10-18 |
2007-04-26 |
Duke University |
Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
|
|
WO2008042814A2
(en)
|
2006-09-29 |
2008-04-10 |
California Institute Of Technology |
Mart-1 t cell receptors
|
|
KR101319499B1
(ko)
|
2008-02-22 |
2013-10-17 |
엘지디스플레이 주식회사 |
화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법
|
|
EP4032552B1
(en)
|
2008-08-26 |
2023-10-04 |
City of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
|
EP2210903A1
(en)
|
2009-01-21 |
2010-07-28 |
Monoclonal Antibodies Therapeutics |
Anti-CD160 monoclonal antibodies and uses thereof
|
|
WO2010124188A1
(en)
|
2009-04-23 |
2010-10-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human ror1 antibodies
|
|
EP2258719A1
(en)
|
2009-05-19 |
2010-12-08 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Multiple target T cell receptor
|
|
EP2496244B8
(en)
|
2009-11-02 |
2017-11-22 |
Emory University |
Drug resistant immunotherapy for treatment of a cancer
|
|
JP6208580B2
(ja)
|
2010-05-17 |
2017-10-04 |
サンガモ セラピューティクス， インコーポレイテッド |
新規のｄｎａ結合タンパク質及びその使用
|
|
US9758586B2
(en)
|
2010-12-01 |
2017-09-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric rabbit/human ROR1 antibodies
|
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
|
DK3252076T3
(da)
|
2011-01-14 |
2019-12-02 |
Univ California |
Diagnostisk anvendelse af antistoffer mod ror-1-protein
|
|
JP6120848B2
(ja)
|
2011-08-15 |
2017-04-26 |
メディミューン，エルエルシー |
抗ｂ７−ｈ４抗体およびその使用
|
|
EP3241902B1
(en)
|
2012-05-25 |
2018-02-28 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
CA2881981A1
(en)
*
|
2012-08-20 |
2014-02-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
PL3489261T3
(pl)
|
2012-08-24 |
2021-08-16 |
The Regents Of The University Of California |
Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
WO2014093718A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
AU2013361275B2
(en)
|
2012-12-19 |
2016-11-24 |
Amplimmune, Inc. |
Anti-human B7-H4 antibodies and their uses
|
|
EP3760719A1
(en)
|
2013-11-18 |
2021-01-06 |
CRISPR Therapeutics AG |
Crispr-cas system materials and methods
|
|
EP3593812A3
(en)
*
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
KR102048855B1
(ko)
*
|
2014-07-29 |
2019-11-26 |
셀렉티스 |
암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체
|
|
JP6943760B2
(ja)
|
2014-09-12 |
2021-10-06 |
ジェネンテック， インコーポレイテッド |
抗ｂ７−ｈ４抗体及び免疫複合体
|
|
JP2017531427A
(ja)
|
2014-10-03 |
2017-10-26 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法
|
|
US10227408B2
(en)
|
2015-02-19 |
2019-03-12 |
Compugen Ltd. |
Anti-PVRIG antibodies and methods of use
|
|
MX2017012939A
(es)
*
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
EP3286211A1
(en)
*
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
WO2016205566A1
(en)
*
|
2015-06-16 |
2016-12-22 |
The Regents Of The University Of California |
Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
|
|
WO2017019767A1
(en)
*
|
2015-07-27 |
2017-02-02 |
Myosotis, Llc |
Inhibition of CXCL12 in Cancer Immunotherapy
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
EP3393504B1
(en)
*
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
|
US20190336504A1
(en)
*
|
2016-07-15 |
2019-11-07 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
WO2019200347A1
(en)
|
2018-04-13 |
2019-10-17 |
Fred Hutchinson Cancer Research Center |
Methods for adoptive cell therapy targeting ror1
|